Persistent hypoxia in bone metastases induces an immunosuppressive environment, limiting the effectiveness of immunotherapies. To address chronic hypoxia, we have developed manganese dioxide (MnO) nanoparticles with tunable oxygen production kinetics for sustained oxygenation in bone metastases lesions. Using polyethylene glycol (PEG)-stabilized MnO or poly(lactic[50]--glycolic[50] acid) (50:50 PLGA), poly(lactic[75]--glycolic[25] acid) (75:25 PLGA), and polylactic acid (PLA)-encapsulated MnO NPs, we demonstrate that polymer hydrophobicity attenuates burst oxygen production and enables tunable oxygen production kinetics.
View Article and Find Full Text PDF